v3.26.1
Consolidated Income Statement - USD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Profit or loss [abstract]      
Product sales, net $ 115,153 $ 11,263 $ 0
Royalty revenue 5,097 5,935 5,902
Total revenues 120,250 17,198 5,902
Cost of revenues (including amortization of currently marketed intangible assets, 2026: $6,126: 2025: $3,937, 2024: $Nil) (16,667) (5,130) 0
Research & development (97,509) (34,807) (39,716)
Selling, general and administration (57,346) (39,309) (24,980)
Fair value remeasurement of contingent consideration 12,057 (14,887) (9,693)
Fair value remeasurement of warrant liability 859 (4,962) 779
Other operating income and expenses 5,308 3,053 2,570
Finance costs (23,839) (22,968) (23,009)
Loss before income tax (56,887) (101,812) (88,147)
Income tax (expense)/benefit (613) (330) 191
Loss attributable to the owners of Mesoblast Limited $ (57,500) $ (102,142) $ (87,956)
Losses per share from continuing operations attributable to the ordinary equity holders of the Group:      
Basic - losses per share (in USD per share) $ (0.0444) $ (0.0846) $ (0.0891)
Diluted - losses per share (in USD per share) $ (0.0444) $ (0.0846) $ (0.0891)